FHTX · Company research
Foghorn Therapeutics Inc. (FHTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80% - Stocktwits | FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80% Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| A more-than-10% owner reports $0.0001 warrants in Foghorn Therapeutics (FHTX). - Stock Titan | A more-than-10% owner reports $0.0001 warrants in Foghorn Therapeutics (FHTX). Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| A 9.99% cap blocked warrant exercise as BVF reported a stake in Foghorn Therapeutics (FHTX). - Stock Titan | A 9.99% cap blocked warrant exercise as BVF reported a stake in Foghorn Therapeutics (FHTX). Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| FHTX stock extends sell-off after Lilly collaboration ends — Wedbush slashes target by 80% - MSN | FHTX stock extends sell-off after Lilly collaboration ends — Wedbush slashes target by 80% MSN | View source ↗ | MSN | Oct 2, 2026 | neutral | 0 | 0.6 |
| Foghorn Therapeutics (FHTX) Shares Slide After Eli Lilly Collabo - GuruFocus | Foghorn Therapeutics (FHTX) Shares Slide After Eli Lilly Collabo GuruFocus | View source ↗ | GuruFocus | Oct 2, 2026 | neutral | 0 | 0.6 |
| Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ) - Seeking Alpha | Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 2, 2026 | neutral | 0 | 0.6 |
| Why Is Foghorn Therapeutics Stock Tumbling Today? - Foghorn Therapeutics (NASDAQ:FHTX) - Benzinga | Why Is Foghorn Therapeutics Stock Tumbling Today? - Foghorn Therapeutics (NASDAQ:FHTX) Benzinga | View source ↗ | Benzinga | Oct 1, 2026 | neutral | 0 | 0.6 |
| FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? - TradingView | FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? TradingView | View source ↗ | TradingView | Oct 1, 2026 | neutral | 0 | 0.6 |
| FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? - Yahoo Finance | FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| FHTX Stock Slides As Traders Eye Key Support Levels - Timothy Sykes | FHTX Stock Slides As Traders Eye Key Support Levels Timothy Sykes | View source ↗ | Timothy Sykes | Oct 1, 2026 | neutral | 0 | 0.6 |
| Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha | Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 1, 2026 | neutral | 0 | 0.6 |
| FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? - Stocktwits | FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? Stocktwits | View source ↗ | Stocktwits | Oct 1, 2026 | neutral | 0 | 0.6 |
| Lilly and Foghorn won't advance two drug programs; Foghorn cuts about 40% of staff. - Stock Titan | Lilly and Foghorn won't advance two drug programs; Foghorn cuts about 40% of staff. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance | Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Simply Wall Street | Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates Simply Wall Street | View source ↗ | Simply Wall Street | Aug 10, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.